Phage Therapy: Going Temperate?

Animals Anti-Bacterial Agents Bacteria / genetics Bacterial Infections / therapy Bacteriophages / classification CRISPR-Cas Systems Drug Resistance, Multiple, Bacterial Endotoxins Genetic Engineering Humans Phage Therapy / methods Transduction, Genetic Virulence
CRISPR-Cas antibiotic resistance phage therapy synthetic biology temperate phages

Journal

Trends in microbiology
ISSN: 1878-4380
Titre abrégé: Trends Microbiol
Pays: England
ID NLM: 9310916

Informations de publication

Date de publication:
04 2019
Historique:
received: 21 07 2018
revised: 29 09 2018
accepted: 23 10 2018
pubmed: 24 11 2018
medline: 23 6 2020
entrez: 24 11 2018
Statut: ppublish

Résumé

Strictly lytic phages have been consensually preferred for phage therapy purposes. In contrast, temperate phages have been avoided due to an inherent capacity to mediate transfer of genes between bacteria by specialized transduction - an event that may increase bacterial virulence, for example, by promoting antibiotic resistance. Now, advances in sequencing technologies and synthetic biology are providing new opportunities to explore the use of temperate phages for therapy against bacterial infections. By doing so we can considerably expand our armamentarium against the escalating threat of antibiotic-resistant bacteria.

Identifiants

DOI: 10.1016/j.tim.2018.10.008 PMID: 30466900
pubmed: 30466900
pii: S0966-842X(18)30231-2
doi: 10.1016/j.tim.2018.10.008
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Endotoxins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

368-378

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Rodrigo Monteiro (R)

CEB - Centre of Biological Engineering, University of Minho, Braga, Portugal.

Diana Priscila Pires (DP)

CEB - Centre of Biological Engineering, University of Minho, Braga, Portugal.

Ana Rita Costa (AR)

CEB - Centre of Biological Engineering, University of Minho, Braga, Portugal; Present address: Department of Bionanoscience, Kavli Institute of Nanoscience, Delft University of Technology, Delft, The Netherlands. Electronic address: a.r.martinscosta@tudelft.nl.

Joana Azeredo (J)

CEB - Centre of Biological Engineering, University of Minho, Braga, Portugal. Electronic address: jazeredo@deb.uminho.pt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Phage Therapy: Going Temperate?
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Phage Therapy: Going Temperate?
questionsmedicales.fr › Bactéries › Phage Therapy: Going Temperate?
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Phage Therapy: Going Temperate?
questionsmedicales.fr › Virus › Bactériophages › Phage Therapy: Going Temperate?
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › Systèmes CRISPR-Cas › Phage Therapy: Going Temperate?
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Multirésistance aux médicaments › Multirésistance bactérienne aux médicaments › Phage Therapy: Going Temperate?
questionsmedicales.fr › Facteurs biologiques › Toxines biologiques › Toxines bactériennes › Endotoxines › Phage Therapy: Going Temperate?
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Génie génétique › Phage Therapy: Going Temperate?
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Phage Therapy: Going Temperate?
questionsmedicales.fr › Thérapeutique › Biothérapie › Phagothérapie › Phage Therapy: Going Temperate?
questionsmedicales.fr › Phénomènes génétiques › Recombinaison génétique › Transduction génétique › Phage Therapy: Going Temperate?
questionsmedicales.fr › Phénomènes microbiologiques › Virulence › Phage Therapy: Going Temperate?